Business Context and Reporting Period
This Form 8-K was filed by Lucid Diagnostics Inc. (LUCD) on December 2, 2022, reporting events that occurred on November 30, 2022. The Company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC. The filing details unregistered sales of equity securities to its parent company, PAVmed Inc., in satisfaction of various contractual obligations.
Key Financial Metrics and Transactions
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. Instead, it reports specific non-cash transactions involving the issuance of common stock to settle liabilities:
- Management Services Agreement (MSA): Issued 750,818 shares to settle $1,650,000 in accrued fees for July, August, and September 2022.
- Payroll and Benefit Expense Reimbursement Agreement (PBERA): Issued 1,479,326 shares to reimburse $2,719,430 in accrued payroll and benefit expenses through Q3 2022.
- CapNostics Assignment Agreement: Issued 1,145,086 shares to settle the $2,100,000 purchase price for CapNostics, LLC interests.
- Total Shares Issued: 3,375,230 shares of common stock were issued in total under these agreements.
Material Changes and Agreements
The filing outlines the formalization and execution of agreements with PAVmed Inc.:
- MSA Terms: The Company pays a monthly fee of $550,000. PAVmed may elect payment in cash or stock (valued at VWAP of the final 10 trading days, subject to a $0.70 floor). There is a cap of 7,709,836 shares issuable under this agreement.
- PBERA Terms: A new agreement formalizes the reimbursement of payroll expenses paid by PAVmed on the Company's behalf. Reimbursements can be made in cash or stock (valued at VWAP, subject to a $0.40 floor), provided Nasdaq share issuance limits are not exceeded without shareholder approval.
- CapNostics Settlement: The Company assumed the obligation to pay the $2.1 million acquisition cost for CapNostics, LLC, previously held by a PAVmed subsidiary, opting to settle via stock issuance.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the transaction details. Key unusual items include:
- Related Party Transactions: All issuances were made to the parent company, PAVmed Inc., or its subsidiary.
- Exemption Reliance: The shares were offered and sold in reliance on the Section 4(a)(2) exemption from registration under the Securities Act.
- Nasdaq Compliance: The PBERA includes a provision preventing share issuance if it would exceed Nasdaq rules for share issuance without shareholder approval.
Investor Verification Checklist
- Verify the current total share count and the dilution impact of the 3,375,230 newly issued shares.
- Confirm the remaining share cap available under the Management Services Agreement (7,709,836 total limit).
- Review the Company's cash position to determine if future MSA fees or PBERA reimbursements will be paid in cash or further stock.
- Check for any subsequent filings regarding shareholder approval if future issuances approach Nasdaq limits.